Back to search results
NCT07642856

Individualized Neuro-Modulation Paired With Cerebellar Therapy

Recruiting
NAAges 18–75InterventionalTreatment
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
~30 participants
Updated 2026-06-11 on ClinicalTrials.gov
What's tested:Therapy

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Scale for the Assessment and Rating of Ataxia (SARA)
Measured over Assessed at pre-treatment, post-treatment, and at 3- and 6-month follow-ups.
+1 more outcome measured

Conditions

Cerebellar Ataxia
Cerebellar Diseases
Cerebellar Stroke
Cerebellar Tumor

Explore related trials

Cerebellar ataxiaCerebellar DegenerationCerebellar disorderCerebellar NeoplasmCerebellar strokeCongenital Cerebellar Hypoplasia

NCT07642856

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Motion Analysis Lab in the Kennedy Krieger Institute

    Baltimore, Marylandstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Amy J Bastian, PhD, PT · PRINCIPAL_INVESTIGATOR · Motion Analysis Lab in the Kennedy Krieger Institute

Who to contact

Derek J Eversley, BS
[email protected]
443-923-2716
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18-75 years
Males and Females
Disorders that predominantly affect the cerebellum: damage from stroke, tumor or degeneration (genetic or non-genetic causes, congenital hypoplasia).

Exclusion

Diagnoses or impairments that interfere with task execution or data interpretation.
Heart pacemaker or other MRI-incompatible implanted metal device
Metallic foreign body in their eye or head
Experience with severe claustrophobia
Experience discomfort from the MRI scan, such as excessive heating of tattoos
Seizures or history of seizure disorder
Alcohol or substance use disorder (self-report)
Diagnosed history of severe psychiatric disorder such as depression, schizophrenia (self-report)
Metallic foreign body in their eye or head (except the mouth e.g. dental fillings)
Specific medications: tricyclic anti-depressants or neuroleptic medication
Any medical condition (including orthopedic, pain, cardiopulmonary or other) that limits safe participation in exercise training

What this trial measures

  • Scale for the Assessment and Rating of Ataxia (SARA)Assessed at pre-treatment, post-treatment, and at 3- and 6-month follow-ups.

    The SARA is a tool for assessing ataxia. SARA is an 8-item performance based scale, yielding a total score of 0 (no ataxia) to 40 (most severe ataxia). The scores are based on patient performance of: gait, stance, sitting, speech disturbance, finger chase, nose-finger test, fast alternating hand movements, heel-shin slide.

  • Patient-Reported Outcome Measure of AtaxiaAssessed at pre-treatment, post-treatment, and at 3- and 6-month follow-ups.

    The PROM-Ataxia is a self reported questionnaire used by researchers to evaluate the daily impact and progression of cerebellar ataxia directly from the patient's perspective. The questionnaire encompasses 70 total items within 3 main domains: 1) Physical: Gait, manual dexterity, swallowing (dysphagia), and visual/ocular motor control. 2) Activities of Daily Living (ADL): Managing household chores, employment, driving, and self-care. 3)Mental: Mood, anxiety, motivation, and cognitive tasks (e.g., multitasking and comprehension).